Table 2.

Tumor HRD score charactersistics

	Samples	Primary-recurrent pairs
Total tumor samples	100	50
Evaluable HRD scores	88% (88/100)	78% (39/50)
High HRD score ( ≥ 42)	57% (50/88)	56% (22/39) a
BRCA1 mutation	26% (26/100)	26% (13/50)
BRCA2 mutation	6% (6/100)	6% (3/50)
BRCA1 methylation	10% (10/100)	12% (6/50) b

^aPositive in both the primary and recurrent specimen

^bPositive in the primary and/or recurrent specimen (two pairs were discordant)